Skip to main content

Table 2 Characteristics of patients with Kaposi sarcoma who were lost to follow-up in four countries in sub-Saharan Africa (N1a + D2 in Fig. 1)

From: Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa

  AMPATH - Kenya N = 233 ISS - Uganda N = 79 Lighthouse - Malawi N = 74 UATH & NHA - Nigeria N = 36 Overall N = 422
Age at last visit, years a 35 (30–42)b 32 (29–40) 34 (29–40) 36 (32–42) 35 (29–41)
Male sex a 62% 68% 78% 51% 65%
ART in use at last visit 82% 77% 47% 58% 73%
CD4+ T-cells /mm 3 at last visit c 126 (39–287) 183 (110–317) 231 (141–387) 259 (177–308) 159 (60–312)
CD4+ T-cells /mm 3 at last visit c , category
 0–50 28% 17% 6.7% 7.7% 22%
 51–100 15% 4.4% 6.7% 7.7% 12%
 101–200 23% 30% 27% 23% 24%
 201–350 18% 30% 33% 46% 24%
 351–500 9.4% 13% 20% 0% 10%
  > 500 7.3% 4.4% 6.7% 15% 7.5%
Duration since KS diagnosis at last visit, months 0.96 (0–3.5) 1.9 (0.3–4.7) 1.9 (0–8.3) 4.7 (0.6–18.1) 1.4 (0.03–5.1)
Duration of being lost at database closure, months 17 (11–22) 30 (19–39) 31 (17–47) 26 (14–46) 21 (13–30)
  1. ART denotes antiretroviral therapy; AMPATH denotes Academic Model Providing Access to Healthcare; ISS denotes Immune Suppression Syndrome; UATH denotes University of Abuja Teaching Hospital; and NHA denotes National Hospital of Abuja
  2. a Age missing for 1 person in AMPATH and 1 person in UATH/NHA; sex is missing for 1 person in UATH/NHA
  3. b median (Interquartile range) unless otherwise noted
  4. c 65% missing CD4 count overall (59% AMPATH, 71% ISS, 80% Lighthouse, and 64% UATH/NHA)